




CORRECTION

Correction to: Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States

Chuka Udeze · Kristin A. Evans  · Yoojung Yang · Timothy Lillehaugen · Janna Manjelienskaia · Urvi Mujumdar · Nanxin Li · Biree Andemariam

Published online: September 11, 2023
© The Author (s) 2023

Correction to: Adv Ther (2023) 40:3543–3558
<https://doi.org/10.1007/s12325-023-02545-7>

An error in Fig. 2b has been corrected; for the subgroup of patients with ≥ 2 VOCs per year and commercial insurance, the sample size should be 437.

An error in Supplementary Fig. 1a has been corrected; the lifetime healthcare costs for the subgroup of patients with ≥ 2 VOCs per year with a life expectancy of 50 years should be \$4.5M.

An error in Supplementary Table 1 has been corrected; the prevalence of gallstones in patients aged ≥ 36 years should be 36 (9.2).

The original article and the supplementary material have been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s12325-023-02545-7>.

C. Udeze · Y. Yang · U. Mujumdar · N. Li
Vertex Pharmaceuticals Incorporated, Boston, MA, USA

K. A. Evans · T. Lillehaugen · J. Manjelienskaia
Merative, Cambridge, MA, USA

B. Andemariam (✉)
Division of Hematology-Oncology, University of Connecticut Health, 263 Farmington Avenue, Farmington, CT 06030, USA
e-mail: andemariam@uchc.edu